Becton, Dickinson & Stock

$175.97

0.86% yesterday

NYSE, Jul 11, 10:00 pm CET

ISIN

US0758871091

Symbol

BDX

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

Becton, Dickinson & Stock price

$175.97

-74.99 29.88% 5Y

NYSE, Closing price Fri, Jul 11 2025

-1.53 0.86%

ISIN

US0758871091

Symbol

BDX

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Health

Industry

Medical specialties

Key metrics

Basic

Market capitalization

$50.4b

Enterprise Value

$69.0b

Net debt

$18.6b

Cash

$683.0m

Shares outstanding

286.6m

Valuation (TTM | estimate)

P/E

33.4 | 12.4

P/S

2.4 | 2.3

EV/Sales

3.3 | 3.2

EV/FCF

26.6

P/B

2.0

Dividends

DPS

$3.80

Yield 1Y | 5Y

2.2% | 1.4%

Growth 1Y | 5Y

4.4% | 4.8%

Payout 1Y | 3Y

64.9% | 65.3%

Increased

25 Years

Financials (TTM | estimate)

Revenue

$20.9b | $22.0b

EBITDA

$5.1b | $6.4b

EBIT

$2.7b | $5.5b

Net Income

$1.5b | $4.1b

Free Cash Flow

$2.6b

Growth (TTM | estimate)

Revenue

5.8% | 9.2%

EBITDA

-0.9% | 24.2%

EBIT

-4.4% | 87.6%

Net Income

15.3% | 140.8%

Free Cash Flow

-14.4%

Financial Health

Equity Ratio

45.2%

Return on Equity

6.6%

ROCE

5.8%

ROIC

Debt/Equity

0.8

EPS

$5.3

FCF per Share

$9.0

Short interest

1.1%

Employees

74k

Rev per Employee

$270.0k

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Get Started for Free Today

Becton, Dickinson & Stock Analysis

Unlock Scores for Free

??

21 Analysts have issued a Becton, Dickinson & forecast:

10x Buy

48%

11x Hold

52%

More details on Analyst Estimates Including Price Targets

21 Analysts have issued a Becton, Dickinson & forecast:

Buy

48%

Hold

52%

Analyst Estimates with Stock Price Targets

Financial data from Becton, Dickinson &

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	20,867 20,867	6% 6% 100%
- Direct Costs	11,553 11,553	6% 6% 55%
Gross Profit	9,314 9,314	6% 6% 45%
- Selling and Administrative Expenses	5,043 5,043	7% 7% 24%
- Research and Development Expense	1,246 1,246	6% 6% 6%
EBITDA	5,095 5,095	1% 1% 24%
- Depreciation and Amortization	2,369 2,369	3% 3% 11%
EBIT (Operating Income) EBIT	2,726 2,726	4% 4% 13%
Net Profit	1,519 1,519	15% 15% 7%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Becton, Dickinson & Stock News

Neutral

PRNewsWire

●

5 days ago

BD Appoints Bilal Muhsin as Executive Vice President and President of Future Connected Care Segment

FRANKLIN LAKES, N.J. , July 7, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that, effective July 2, Bilal Muhsin has been named executive vice president and will become the president of BD's future Connected Care segment, as part of the company's previously announced plans to update its structure as it advances...

Positive

Seeking Alpha

●

8 days ago

Buy 3 IDEAL Dividend Kings Of 25 'Safer' In July's 55

Most Dividend Kings are overpriced, but six currently offer fair value, with annual dividends from $1,000 invested exceeding their share prices. Top-yielding Dividend Kings like Altria, Northwest Natural, and United Bankshares meet my 'dogcatcher ideal' for income-focused investors. Analyst forecasts suggest select Dividend Kings could deliver 13-28% total returns by July 2026, with lower volat...

Positive

24/7 Wall Street

●

10 days ago

3 Undervalued Dividend King Stocks With Over 50% Upside Potential

As we enter the second half of 2025, now is the perfect time to invest in dividend stocks — especially those with quality underlying fundamentals that pay high dividend yields.

More Becton, Dickinson & News

Company Profile

Becton, Dickinson & Co. is a medical technology company. The firm engages in the development, manufacture and sale of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. It operates through the following segments: BD Medical, BD Life Sciences and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections and cancers. The BD Interventional segment provides vascular, urology, oncology and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via Homecare business. The company was founded in 1897 and is headquartered in Franklin Lakes, NJ.

Head office	United States
CEO	Thomas Polen
Employees	74,000
Founded	1897
Website	www.bd.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now